eFFECTOR Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- eFFECTOR Therapeutics, Inc. (EFTR), a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Solana Beach, California, develops selective translation regulator inhibitors (STRIs) targeting the eIF4F complex and its activating kinase MNK1/2 for oncology indications; its lead product candidates include tomivosertib (eFT508), an oral small-molecule MNK1/2 inhibitor evaluated in a Phase 2b KICKSTART trial in combination with pembrolizumab for metastatic non-small cell lung cancer (NSCLC), and zotatifin (eFT226), a small-molecule eIF4A inhibitor assessed in Phase 1/2 trials as monotherapy and in combinations such as with fulvestrant and abemaciclib for ER+ breast cancer, with sotorasib for KRAS G12C-mutant NSCLC, and in ER+ endometrial cancer and low-grade serous ovarian cancer via collaboration with Dana-Farber Cancer Institute; the company maintains a global research collaboration and license agreement with Pfizer Inc. to develop eIF4E inhibitors. Operations span the United States with a focus on precision oncology for biomarker-positive solid tumors including NSCLC, breast cancer, and others driven by dysregulated mRNA translation. In June 2024, eFFECTOR announced a wind-down of operations, terminated employees, appointed Craig R. Jalbert as CEO, President, Treasurer, Secretary, and sole board member to manage the process and pursue strategic alternatives for its pipeline assets, and voluntarily requested delisting from Nasdaq due to non-compliance with listing standards; the company is no longer operating as of 2025, with correspondence directed to Foxboro, Massachusetts, and prior SEC filings available publicly.
Comparing eFFECTOR Therapeutics (NASDAQ:EFTR) and Orgenesis (NASDAQ:ORGS)
eFFECTOR Therapeutics (NASDAQ:EFTR) & NexImmune (NASDAQ:NEXI) Critical Contrast
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
eFFECTOR Therapeutics Announces Reverse Stock Split
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer